PolyPeptide Group AG
SIX:PPGN
PolyPeptide Group AG
SIX:PPGN
Price:
23.95
CHF
-3.62%
Market Closed
Market Cap:
CHf793.5m
PolyPeptide Group AG
EPS (Diluted)
Last
Value
3 Years
3Y
CAGR
5 Years
5Y
CAGR
10 Years
10Y
CAGR
|
See Also
PolyPeptide Group AG
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
PolyPeptide Group AG
SIX:PPGN
|
EPS (Diluted)
€0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bachem Holding AG
SIX:BANB
|
EPS (Diluted)
CHf1
|
CAGR 3-Years
10%
|
CAGR 5-Years
14%
|
CAGR 10-Years
15%
|
|
|
Siegfried Holding AG
SIX:SFZN
|
EPS (Diluted)
CHf3
|
CAGR 3-Years
2%
|
CAGR 5-Years
25%
|
CAGR 10-Years
N/A
|
|
|
Lonza Group AG
SIX:LONN
|
EPS (Diluted)
CHf13
|
CAGR 3-Years
-6%
|
CAGR 5-Years
3%
|
CAGR 10-Years
11%
|
|
|
Tecan Group AG
SIX:TECN
|
EPS (Diluted)
CHf4
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
N/A
|
|
|
SKAN Group AG
SIX:SKAN
|
EPS (Diluted)
CHf1
|
CAGR 3-Years
27%
|
CAGR 5-Years
0%
|
CAGR 10-Years
N/A
|
|
No Stocks Found
PolyPeptide Group AG
Glance View
PolyPeptide Group AG is a contract development and manufacturing organization for clinical and approved commercial-stage peptide drug substances used in peptide-based therapeutics. The company is headquartered in Zug, Zug and currently employs 1,041 full-time employees. The company went IPO on 2021-04-29.
PPGN Intrinsic Value
HIDDEN
See Also
What is PolyPeptide Group AG's EPS (Diluted)?
EPS (Diluted)
-0.6
EUR
-0.6
EUR
Based on the financial report for Dec 31, 2024, PolyPeptide Group AG's EPS (Diluted) amounts to -0.6 EUR.
What is PolyPeptide Group AG's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 1Y
62%
62%
Over the last year, the EPS (Diluted) growth was 62%.
